Shots:

• The first participants has been dosed in the P-I/II clinical study to evaluate VAX-24 vs Prevnar 20 in healthy adults with IPD and Pneumonia at ~13 sites in the US. The results are expected at the end of 2022
• The P-I of the study is to evaluate the safety and tolerability of a single inj. of VAX-24 at three dose levels in 64 healthy adults aged 18 to 49yrs. while the P-II portion of the study will evaluate the safety, tolerability, and immunogenicity of VAX-24 in ~800 healthy adults aged 50 to 64yrs.
• The prespecified immunogenicity EPs of the P-II portion of the study include an assessment of the induction of Ab responses using IgG and OPA at three doses

 Ref: Globe Newswire | Image: Vaxcyte